Abstract
Despite advancements in lowering blood pressure, the best approach to lower it remains controversial because of the lack of information on the molecular basis of hypertension. We, therefore, performed plasma proteomics of plasma from patients with hypertension to identify molecular determinants detectable in these subjects but not in controls and vice versa. Plasma samples from hypertensive subjects (cases; n=118) and controls (n=85) from the InGenious HyperCare cohort were used for this study and performed mass spectrometric analysis. Using biostatistical methods, plasma peptides specific for hypertension were identified, and a model was developed using least absolute shrinkage and selection operator logistic regression. The underlying peptides were identified and sequenced offline using matrix-assisted laser desorption ionization orbitrap mass spectrometry. By comparison of the molecular composition of the plasma samples, 27 molecular determinants were identified differently expressed in cases from controls. Seventy percent of the molecular determinants selected were found to occur less likely in hypertensive patients. In cross-validation, the overall R-2 was 0.434, and the area under the curve was 0.891 with 95% confidence interval 0.8482 to 0.9349, P
Original language | English |
---|---|
Pages (from-to) | 412-419 |
Number of pages | 8 |
Journal | Hypertension |
Volume | 70 |
Issue number | 2 |
DOIs | |
Publication status | Published - Aug 2017 |
Keywords
- antihypertensive agents
- blood pressure
- confidence intervals
- hypertension
- proteomics
- CENTER KINASE FAMILY
- BLOOD-PRESSURE
- L-TRYPTOPHAN
- PULMONARY-HYPERTENSION
- ANTIHYPERTENSIVE DRUGS
- ARTERIAL-HYPERTENSION
- OUTCOME INCIDENCE
- EUROPEAN-SOCIETY
- TIGHT JUNCTIONS
- PROTEINS